Chimerix (CMRX) Shares Lose Over -70 Percent after Antiviral Drug Fails Phase 3 Trial

Shares of Chimerix Inc. (CMRX) were trading down -27.92 or -78.49 percent to $7.65 per share in Monday's premarket trading after the company announced early this morning that its lead product candidate had failed to meet its primary endpoint in a Phase 3 trial. Chimerix stock closed at $35. 57 per share in Friday's regular ... READ MORE Read the rest of Chimerix (CMRX) Shares Lose Over -70 Percent after Antiviral Drug Fails Phase 3 Trial at InvestorGuide.com .